Finland· FI-REL-REL61529
Triumeq
A lamivudine, abacavir and dolutegravir product containing dolutegravir sodium + abacavir sulfate + lamivudine, registered in Finland by ViiV Healthcare BV. The same ATC class is registered in 13 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Lamivudine, abacavir and dolutegravir is registered in 13 of 19 countries.
Countries holding a registration under ATC J05AR13 (lamivudine, abacavir and dolutegravir), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 8 of them publish a price we can compare per daily dose
Lamivudine, abacavir and dolutegravir · ATC J05AR13
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Fimea (Finland)- Active substance
- Dolutegravir sodium + Abacavir sulfate + Lamivudine
- Manufacturer
- ViiV Healthcare BV
- Country
- Finland (FI)
- ATC code
- J05AR13
- ATC class
- Lamivudine, abacavir and dolutegravir
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
2 interactions on record for lamivudine, abacavir and dolutegravir.
Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Lamivudine, abacavir and dolutegravir · interactions on record
2 records
2 more interactions with mechanism and management, from a commercially licensed source.
Sign in to checkSame medicine, other countries
Lamivudine, abacavir and dolutegravir in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaTRIUMEQViiV Healthcare BV, Amersfoort
- SpainTRIUMEQ 5 MG/60 MG/30 MG COMPRIMIDOS DISPERSABLESViiv Healthcare B.V.
- FranceTRIUMEQ 5 mg/60 mg/30 mg, comprimé dispersibleVIIV HEALTHCARE (PAYS-BAS)
- United KingdomTriumeq 50mg/600mg/300mg tabletsViiV Healthcare UK Ltd
- IrelandTriumeq 5 mg/60 mg/30 mg dispersible tabletsViiV Healthcare BV
- IcelandTriumeqViiV Healthcare BV
- NetherlandsTriumeq 5 mg/ 60 mg/ 30 mg dispergeerbare tablettenViiV Healthcare B.V.
- NorwayTriumeqViiV Healthcare BV
Authorised across Europe · EMA
The same active substance is authorised in 5 EEA countries. Names it is sold under:
- Iceland · Triumeq
- Liechtenstein · Triumeq
- Malta · Dolutegravir/Abacavir/Lamivudine Pharos
- Norway · Triumeq
- Portugal · Dolutegravir/Abacavir/Lamivudine Pharos
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ba0205a2-240a-422c-b4fe-92ebec84408f GET /v1/drugs/ba0205a2-240a-422c-b4fe-92ebec84408f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": "10",
"form": "dispergoituva tabletti",
"route": "Suun kautta",
"ddd_unit": "ED",
"strength": "5 mg / 60 mg / 30 mg",
"atc_label": "lamivudiini, abakaviiri ja dolutegraviiri",
"ma_number": null,
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": "EU/1/14/940/003",
"fimea_rel_id": "REL61529",
"authorised_at": "2023-02-20"
}See everything about lamivudine, abacavir and dolutegravir.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.